VTAK Stock Summary and Trading Ideas (Catheter Precision | AMEX:VTAK)

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.

Catheter Precision trades on the AMEX stock market under the symbol VTAK.

As of July 2, 2026, VTAK stock price declined to $0.79 with 182,354 million shares trading.

VTAK has a beta of 0.77, meaning it tends to be less sensitive to market movements. VTAK has a correlation of 0.00 to the broad based SPY ETF.

VTAK has a market cap of $2.13 million. This is considered a Sub-Micro Cap stock.

VTAK has outperformed the market in the last year with a return of +223.8%, while the SPY ETF gained +21.3%. However, in the most recent history, VTAK shares have underperformed the stock market with its stock returning -15.1% in the last 3 month period and -6.0% for the last 2 week period, while SPY has returned +13.9% and -0.3%, respectively.

VTAK support price is $.77 and resistance is $.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTAK shares will trade within this expected range on the day.